Loading...
XNYS
ELAN
Market cap10bUSD
Dec 04, Last price  
21.99USD
1D
-0.86%
1Q
19.32%
IPO
-35.51%
Name

Elanco Animal Health Inc

Chart & Performance

D1W1MN
XNYS:ELAN chart
P/E
32.33
P/S
2.46
EPS
0.68
Div Yield, %
Shrs. gr., 5y
6.07%
Rev. gr., 5y
7.65%
Revenues
4.44b
+0.50%
2,909,100,0002,913,500,0002,889,000,0003,066,800,0003,071,000,0003,273,300,0004,765,000,0004,418,000,0004,417,000,0004,439,000,000
Net income
338m
P
-210,800,000-47,900,000-310,700,00086,500,00067,900,000-560,100,000-472,000,000-74,000,000-1,231,000,000338,000,000
CFO
541m
+99.63%
6,600,000155,900,000173,800,000487,300,000224,100,000-41,000,000483,000,000452,000,000271,000,000541,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. The company is headquartered in Greenfield, Indiana and currently employs 5,590 full-time employees. The firm offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The company provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The company also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The company also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. The company also provides products in poultry and aquaculture production.
IPO date
Sep 20, 2018
Employees
5,760
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT